McClanahan Fabienne, Riches John C, Miller Shaun, Day William P, Kotsiou Eleni, Neuberg Donna, Croce Carlo M, Capasso Melania, Gribben John G
Centre for Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London, London, United Kingdom; Department of Molecular Genetics, German Cancer Research Center, Heidelberg, Germany;
Centre for Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London, London, United Kingdom;
Blood. 2015 Jul 9;126(2):212-21. doi: 10.1182/blood-2015-02-626754. Epub 2015 May 15.
T-cell defects, immune suppression, and poor antitumor immune responses are hallmarks of chronic lymphocytic leukemia (CLL), and PD-1/PD-L1 inhibitory signaling has emerged as a major immunosuppressive mechanism. However, the effect of different microenvironments and the confounding influence of aging are poorly understood. The current study uses the Eμ-TCL1 mouse model, which replicates human T-cell defects, as a preclinical platform to longitudinally examine patterns of T-cell dysfunction alongside developing CLL and in different microenvironments, with a focus on PD-1/PD-L1 interactions. The development of CLL was significantly associated with changes in T-cell phenotype across all organs and function. Although partly mirrored in aging wild-type mice, CLL-specific T-cell changes were identified. Murine CLL cells highly expressed PD-L1 and PD-L2 in all organs, with high PD-L1 expression in the spleen. CD3(+)CD8(+) T cells from leukemic and aging healthy mice highly expressed PD-1, identifying aging as a confounder, but adoptive transfer experiments demonstrated CLL-specific PD-1 induction. Direct comparisons of PD-1 expression and function between aging CLL mice and controls identified PD-1(+) T cells in CLL as a heterogeneous population with variable effector function. This is highly relevant for therapeutic targeting of CD8(+) T cells, showing the potential of reprogramming and selective subset expansion to restore antitumor immunity.
T细胞缺陷、免疫抑制和抗肿瘤免疫反应低下是慢性淋巴细胞白血病(CLL)的特征,而PD-1/PD-L1抑制信号已成为主要的免疫抑制机制。然而,不同微环境的影响以及衰老的混杂影响尚不清楚。当前研究使用Eμ-TCL1小鼠模型(该模型可复制人类T细胞缺陷)作为临床前平台,纵向研究在CLL发生过程中以及在不同微环境下T细胞功能障碍的模式,重点关注PD-1/PD-L1相互作用。CLL的发展与所有器官中T细胞表型和功能的变化显著相关。尽管在衰老的野生型小鼠中部分有所体现,但仍识别出了CLL特异性的T细胞变化。小鼠CLL细胞在所有器官中均高度表达PD-L1和PD-L2,脾脏中PD-L1表达较高。白血病小鼠和衰老健康小鼠的CD3(+)CD8(+) T细胞均高度表达PD-1,表明衰老为一个混杂因素,但过继转移实验证明了CLL特异性的PD-1诱导。对衰老CLL小鼠和对照之间PD-1表达和功能的直接比较表明,CLL中的PD-1(+) T细胞是具有可变效应器功能的异质性群体。这对于CD8(+) T细胞的治疗靶向具有高度相关性,显示了重新编程和选择性亚群扩增以恢复抗肿瘤免疫力的潜力。